Stem cell therapy for multiple sclerosis

• May 3, 2024

It has only been in recent times that most of the associated alterations with the initial stages of multiple sclerosis (MS) can be reversed. This works by restoring the immune system, making use of its own stem cells.

This type of treatment requires more clinical trials to confirm the results of the test. However, this therapy is a good prognosis for those who are still in the early stages of this disease.

The best treatment for MS is to stop the attacks immediately before there is further damage to the nerve cells.

Stem cell treatment

A study was done on stem cell therapy and multiple sclerosis. The patients were 12 women and 11 men, and all had an early onset of the relapsing remitting type of MS. These people were chosen because their system had not responded positively to treatment with interferon beta, even after half a year.

His stem cells were transplanted to his bone marrow. Subsequently, drugs were used to destroy the immune cells present, before re-injecting the stem cells. The injected stem cells again recognize myelin.

After three years of treatment, 17 of the total patients had an improvement of the standard disability scale and none died.

Reversal of disability

Scientists say this is the first time that the reversal of disability associated with multiple sclerosis has been effectively done, although they admit that additional tests are needed to confirm the discovery.

Over time, and thanks to the transplant of stem cells, people with MS will not be forced to use drugs. On the other hand, stem cell transplantation is a good one, since it is a one-time therapy.

Words from the MS Society

Speakers from the MS Society have praised stem cell transplants for their positive results. In addition to stopping the progression of the disease, damage to nerve conduction is also reversed. Currently, the healing potential of stem cells becomes more and more recognized.

Video Medicine: Stem Cell Treatment for Multiple Sclerosis - Jason Upshaw with Neil Riordan, PhD (May 2024).